Drug Profile
SAR 440234
Alternative Names: SAR-440234Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator
- Developer Sanofi
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 17 Mar 2021 Phase I/II trials is still ongoing for Acute myeloid leukaemia, Myelodysplastic syndromes, Precursor cell lymphoblastic leukaemia-lymphoma in France, USA (NCT03594955)
- 05 Jan 2021 Sanofi terminated the phase I/II trial in Acute myeloid leukaemia, Myelodysplastic syndromes and Precursor cell lymphoblastic leukaemia-lymphoma (In adolescents, In the elderly, Second-line therapy or greater, In adults) in USA and France (IV) due to Sponsor's decision (NCT03594955) (EudraCT2017-004148-39)
- 23 Jan 2020 Sanofi re-initiates a phase I/II trial in Precursor cell lymphoblastic leukaemia-lymphoma, Myelodysplastic syndromes and Acute myeloid leukaemia (In adolescents, In adults, In the elderly, Second-line therapy or greater) in France (IV) (NCT03594955)